A commentary on “Primary tumor removal improves the prognosis in patients with stage IV breast cancer: A population-based study (cohort study)” (Int J Surg 2020; 83: 109–114)

2021 ◽  
pp. 106029
Author(s):  
Jing Gao ◽  
Xiaoli Xu
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Primary Tumor ◽  
Stage Iv ◽  
Population Based ◽  
Study Cohort ◽  
Tumor Removal ◽  
Population Based Study ◽  
Stage Iv Breast Cancer

scholarly journals Primary tumor removal improves the prognosis in patients with stage IV breast cancer: A population-based study (cohort study)

2020 ◽  
Vol 83 ◽  
pp. 109-114
Author(s):  
Nan Yao ◽  
Wenqiang Li ◽  
Tong Liu ◽  
Sarah Tan Siyin ◽  
Xiufeng Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Primary Tumor ◽  
Stage Iv ◽  
Population Based ◽  
Study Cohort ◽  
Tumor Removal ◽  
Population Based Study ◽  
Stage Iv Breast Cancer

Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study

2018 ◽  
Vol 18 (1) ◽  
pp. e97-e105 ◽  
Author(s):  
Wei Chen ◽  
Ying Huang ◽  
Gary D. Lewis ◽  
Sean S. Szeja ◽  
Sandra S. Hatch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Treatment Outcomes ◽  
Stage Iv ◽  
Population Based ◽  
Population Based Study ◽  
Stage Iv Breast Cancer ◽  
Male Patients

scholarly journals Hormone receptor status may impact the survival benefit of surgery in stage IV breast cancer: a population-based study

Oncotarget ◽  
2016 ◽  
Vol 7 (43) ◽  
pp. 70991-71000 ◽  
Author(s):  
Yinuo Tan ◽  
Xiaofen Li ◽  
Haiyan Chen ◽  
Yeting Hu ◽  
Mengjie Jiang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Survival Benefit ◽  
Stage Iv ◽  
Population Based ◽  
Hormone Receptor Status ◽  
Population Based Study ◽  
Receptor Status ◽  
Stage Iv Breast Cancer

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015 ◽  
Vol 24 (6) ◽  
pp. 920-928 ◽  
Author(s):  
A. Bertaut ◽  
M. Mounier ◽  
I. Desmoulins ◽  
S. Guiu ◽  
F. Beltjens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Stage Iv ◽  
Population Based ◽  
Population Based Study ◽  
Stage Iv Breast Cancer

Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 89-89
Author(s):  
D. H. A. Nguyen ◽  
P. T. Truong ◽  
M. Lesperance ◽  
C. Alexander ◽  
C. V. Walter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Tumor ◽  
Performance Status ◽  
Multivariable Analysis ◽  
Stage Iv ◽  
Study Cohort ◽  
Locoregional Treatment ◽  
Metastatic Lesions ◽  
Stage Iv Breast Cancer ◽  
Er Positive

89 Background: To determine whether locoregional treatment (LRT) of the primary tumor improves outcomes in patients with stage IV breast cancer at diagnosis. Methods: The study cohort comprised 733 women referred from 1996 to 2005 to a population-based cancer institution with clinical or pathologic M1 breast cancer at diagnosis. Patient, tumor, and treatment characteristics were compared between women who were treated with (n=378) and without LRT (n=355) of the primary tumor. Five-year Kaplan-Meier overall survival (OS) and locoregional progression-free survival (LRPFS) were compared between groups. Multivariable analysis to control for potential confounding factors was performed using Cox regression modeling. Results: LRT consisted of surgery alone in 67%, radiotherapy alone in 22%, and both in 11% of patients. LRT use was significantly associated with age <50 years, ECOG performance status 0-1, T1-2 tumors, and N0-1 disease, (all p<0.05). Subjects with less metastatic disease burden and those asymptomatic from the M1 disease were more likely to undergo LRT (p<0.001). Systemic therapy was used in 92% and 85% of patients treated with vs. without LRT, respectively. Five-year OS rates in the LRT and no LRT cohorts were 21% vs 14% (p<0.001). The 5-year LRPFS rates were 72% vs 46% (p<0.001). Among 378 patients who underwent LRT, 5-year OS rates were higher in patients with age <50, ECOG 0-1, ER positive disease, clear surgical margins, single M1 subsite, bone only metastases, and 1-3 metastatic lesions (all p<0.003). Type of LRT (surgery vs radiotherapy vs both) and type of surgery (lumpectomy vs mastectomy) were not associated with 5-year OS (all p>0.05). On multivariable analysis, LRT was associated with improved OS (hazard ratio 0.78, 95% confidence interval 0.64-0.94, p=0.009). Conclusions: LRT of the primary disease was associated with improved survival in women with stage IV breast cancer at diagnosis. Among subjects treated with LRT, the most favorable survival rates were observed in patients with young age, good performance status, ER-positive disease, clear resection margins and in those with distant disease limited to one subsite, bone only, or fewer than 4 metastatic lesions.

Sign in / Sign up

Export Citation Format

Share Document